DiaSorin launches the new LIAISON® Legionella Urinary Antigen Immunodiagnostic Assay in all countries accepting the CE Mark as an aid to the diagnosis of the Legionnaires’ Disease (LD), a life-threatening atypical Community Acquired Pneumonia (CAP).
Read the press release


DiaSorin launches the LIAISON® BRAHMS MR-proADMTM assay in all countries accepting the CE mark to improve patient management by providing the assessment of disease severity.
Read the press release


Euromeadlab 2023: we look forward to seeing you at our booth #120 and at our  EDU Workshop  5 "New testing solutions to enhance patient management in specialized infection at the Emergency Department admission” on 22/05/23 14.30-15.30


We look forward to seeing you at our booth #3. October 6-7, 2022 - Milan, Italy - Cloisters of San Barnaba


We look forward to seeing you at our booth#1-24 Pav. 2 and at our symposium "Improving patient health care in COVID-19 era" on Tuesday 26 April 2022 08:30 – 10:30


The acquisition of Luminex Corporation represents an important step in the expansion strategy of DiaSorin…
Read the press release


Integrated Symposium Diagnosis and immune response of SARS-CoV-2 infection, Flash session TrimericS IgG serology assay in heterologous vaccination.
Register to access


DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG assay, a new quantitative serology test for determination of IgG antibodies against SARS-CoV-2.
Read the press release


DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients.
Read the press release

DiaSorin  announces the launch of a fully automated serology test to detect antibodies against Sars-CoV-2 in Covid-19 patients within the end of April 2020 
DiaSorin Molecular LLC, a division of DiaSorin S.p.A., has received the Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swab specimens. Read the press release
Visit our booth #Z5.C30 and discover our new solution.
Medlab Middle East , 
Dubai World Trade Centre, 3 - 6 February 2020
Christopher Labdon - Lab Manager at Southampton General Hospital (UK) - speaks about the clinical utility and his experience with the new fully automated LIAISON® QuantiFERON®-TB Gold Plus assay

New approaches to latent TB detection and treatment.

May 22nd, 14:45 – 15:45 ROOM 113 – LEVEL 1

At Euromedlab Barcelona 2019


DiaSorin is pleased to announce the US launch of the FDA-Cleared LIAISON® Calprotectin test for the quantitative measurement of Calprotectin in stool samples. Following the recently announced strategic collaboration with Meridian Bioscience to sell Helicobacter pylori stool antigen test, DiaSorin continues to expand its Gastro-Intestinal portfolio in the United States


DiaSorin  and QIAGEN® N.V. today announced the launch in the CE market of the LIAISON® QuantiFERON®-TB Gold Plus as an aid to detect latent tuberculosis infection (LTBI) on LIAISON® analyzer systems. The new test was developed in a partnership between DiaSorin and QIAGEN®.


DiaSorin receives clearance from the CE Notified Body to market the LIAISON® XL Murex Anti-HDV assay for the diagnosis of Hepatitis D virus (HDV) infection enlarging its CLIA menu for hepatitis on LIAISON® platforms.


DiaSorin  is pleased to announce the launch of the new LIAISON® test for the measurement of SHBG (Sex Hormone-Binding Globulin) in human serum and plasma, available worldwide with the exception of the U.S. SGHB, which is produced in the liver, is involved in transport of sex steroids, such as dihydrotestosterone, testosterone and estradiol, in the blood stream. The combined measurement of SHBG and testosterone levels helps determining causes of infertility, decreased libido and erectile dysfunction in men, and diagnosing polycystic ovarian syndrome (PCOS) in women.


The 3 main renal biomarkers (FGF 23, 1,25 vit D, 1-84 PTH) in full automation to support the clinical outcome

17.00 - 18.00 - MITROPULOS HALL


DiaSorin launches the new LIAISON® XL Zika Capture IgM, the first and the only  fully automated test for specific and accurate diagnosis of Zika virus infection,  following  the Emergency Use Authorization (EUA) obtained in the United States over the past few weeks.